Phospho-Trk B (Tyr706) Antibody - #AF3461

(18)   (9)  
Product: Phospho-Trk B (Tyr706) Antibody
Catalog: AF3461
Description: Rabbit polyclonal antibody to Phospho-Trk B (Tyr706)
Application: WB IHC IF/ICC
Cited expt.: WB
Reactivity: Human, Mouse, Rat
Prediction: Horse, Sheep, Rabbit, Chicken
Mol.Wt.: 90~145kDa; 92kD(Calculated).
Uniprot: Q16620
RRID: AB_2834899

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Horse(100%), Sheep(100%), Rabbit(100%), Chicken(100%)
Clonality:
Polyclonal
Specificity:
Phospho-Trk B (Tyr706) Antibody detects endogenous levels of Trk B only when phosphorylated at Tyrosine 706.
RRID:
AB_2834899
Cite Format: Affinity Biosciences Cat# AF3461, RRID:AB_2834899.
Conjugate:
Unconjugated.
Purification:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

AI848316; BDNF tropomyosine receptor kinase B; BDNF/NT 3 growth factors receptor; BDNF/NT-3 growth factors receptor; Brain derived neurotrophic factor receptor; C030027L06Rik; EC 2.7.10.1; GP145 TrkB; GP145-TrkB; GP145-TrkB/GP95-TrkB; GP95 TrkB; Neurotrophic receptor tyrosine kinase 2; Neurotrophic tyrosine kinase receptor type 2; Neurotrophin receptor tyrosine kinase type 2; NTRK 2; Ntrk2; NTRK2_HUMAN; Obesity, hyperphagia, and developmental delay, included; RATTRKB1; Tkrb; Trk B; Trk-B; TRKB; TrkB tyrosine kinase; TRKB1; Tropomyosin related kinase B; tyrosine kinase receptor B; Tyrosine receptor kinase B;

Immunogens

Immunogen:

A synthesized peptide derived from human Trk B around the phosphorylation site of Tyr706.

Uniprot:

Q16620(NTRK2_HUMAN) >>Visit HPA database.

Gene(ID):
NTRK2(4915)
Expression:
Q16620 NTRK2_HUMAN:

Isoform TrkB is expressed in the central and peripheral nervous system. In the central nervous system (CNS), expression is observed in the cerebral cortex, hippocampus, thalamus, choroid plexus, granular layer of the cerebellum, brain stem, and spinal cord. In the peripheral nervous system, it is expressed in many cranial ganglia, the ophthalmic nerve, the vestibular system, multiple facial structures, the submaxillary glands, and dorsal root ganglia. Isoform TrkB-T1 is mainly expressed in the brain but also detected in other tissues including pancreas, kidney and heart. Isoform TrkB-T-Shc is predominantly expressed in the brain.

Description:
This gene encodes a member of the neurotrophic tyrosine receptor kinase (NTRK) family. This kinase is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway. Signalling through this kinase leads to cell differentiation.
Sequence:
MSSWIRWHGPAMARLWGFCWLVVGFWRAAFACPTSCKCSASRIWCSDPSPGIVAFPRLEPNSVDPENITEIFIANQKRLEIINEDDVEAYVGLRNLTIVDSGLKFVAHKAFLKNSNLQHINFTRNKLTSLSRKHFRHLDLSELILVGNPFTCSCDIMWIKTLQEAKSSPDTQDLYCLNESSKNIPLANLQIPNCGLPSANLAAPNLTVEEGKSITLSCSVAGDPVPNMYWDVGNLVSKHMNETSHTQGSLRITNISSDDSGKQISCVAENLVGEDQDSVNLTVHFAPTITFLESPTSDHHWCIPFTVKGNPKPALQWFYNGAILNESKYICTKIHVTNHTEYHGCLQLDNPTHMNNGDYTLIAKNEYGKDEKQISAHFMGWPGIDDGANPNYPDVIYEDYGTAANDIGDTTNRSNEIPSTDVTDKTGREHLSVYAVVVIASVVGFCLLVMLFLLKLARHSKFGMKGPASVISNDDDSASPLHHISNGSNTPSSSEGGPDAVIIGMTKIPVIENPQYFGITNSQLKPDTFVQHIKRHNIVLKRELGEGAFGKVFLAECYNLCPEQDKILVAVKTLKDASDNARKDFHREAELLTNLQHEHIVKFYGVCVEGDPLIMVFEYMKHGDLNKFLRAHGPDAVLMAEGNPPTELTQSQMLHIAQQIAAGMVYLASQHFVHRDLATRNCLVGENLLVKIGDFGMSRDVYSTDYYRVGGHTMLPIRWMPPESIMYRKFTTESDVWSLGVVLWEIFTYGKQPWYQLSNNEVIECITQGRVLQRPRTCPQEVYELMLGCWQREPHMRKNIKGIHTLLQNLAKASPVYLDILG

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Horse
100
Sheep
100
Chicken
100
Rabbit
100
Pig
0
Bovine
0
Dog
0
Xenopus
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity (By similarity). Receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2. Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades. Through SHC1, FRS2, SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for instance neuronal differentiation including neurite outgrowth. Through the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade that mainly regulates growth and survival. Through PLCG1 and the downstream protein kinase C-regulated pathways controls synaptic plasticity. Thereby, plays a role in learning and memory by regulating both short term synaptic function and long-term potentiation. PLCG1 also leads to NF-Kappa-B activation and the transcription of genes involved in cell survival. Hence, it is able to suppress anoikis, the apoptosis resulting from loss of cell-matrix interactions. May also play a role in neutrophin-dependent calcium signaling in glial cells and mediate communication between neurons and glia.

PTMs:

Phosphorylated. Undergoes ligand-mediated autophosphorylation that is required for interaction with SHC1 and PLCG1 and other downstream effectors. Isoform TrkB-T-Shc is not phosphorylated.

Ubiquitinated. Undergoes polyubiquitination upon activation; regulated by NGFR. Ubiquitination regulates the internalization of the receptor (By similarity).

Subcellular Location:

Cell membrane>Single-pass type I membrane protein. Endosome membrane>Single-pass type I membrane protein. Early endosome membrane. Cell projection>Axon. Cell projection>Dendrite. Cytoplasm>Perinuclear region. Cell junction>Synapse>Postsynaptic density.
Note: Internalized to endosomes upon ligand-binding.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Isoform TrkB is expressed in the central and peripheral nervous system. In the central nervous system (CNS), expression is observed in the cerebral cortex, hippocampus, thalamus, choroid plexus, granular layer of the cerebellum, brain stem, and spinal cord. In the peripheral nervous system, it is expressed in many cranial ganglia, the ophthalmic nerve, the vestibular system, multiple facial structures, the submaxillary glands, and dorsal root ganglia. Isoform TrkB-T1 is mainly expressed in the brain but also detected in other tissues including pancreas, kidney and heart. Isoform TrkB-T-Shc is predominantly expressed in the brain.

Family&Domains:

Belongs to the protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily.

Research Fields

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Human Diseases > Substance dependence > Alcoholism.

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

References

1). Intranasal delivery of engineered extracellular vesicles loaded with miR-206-3p antagomir ameliorates Alzheimer's disease phenotypes. Theranostics, 2024 (PubMed: 39659569) [IF=12.4]
2). PLCβ4 driven by cadmium-exposure during gestation and lactation contributes to cognitive deficits by suppressing PIP2/PLCγ1/CREB/BDNF signaling pathway in male offspring. Journal of hazardous materials, 2024 (PubMed: 38820747) [IF=12.2]

Application: WB    Species: Rat    Sample: hippocampus

Fig. 6. PLCβ4 is activated by mGluR1 to suppress the PIP2/PLCγ1/CREB/BDNF signaling pathway in hippocampal neurons. A) Immunoblots and quantification of mGluR1, PLCβ4, p-CREB and BDNF in neurons after 2 μM CdCl2 (Cd2) exposure, n = 3. B-E) The expression of mGluR1 in the hippocampus of male offspring following maternal Cd exposure at PND 21 B), PND 35 C), PND 56 D), and in old age E) was assessed by western blotting, n = 4/6/7/8. F-J) After transfection with 60 nM si-PLCβ4 for 24 h, a final concentration of 10 μM mGluR1 agonist (Ro-01–6128) was administered to hippocampal neurons for 24 h. F-J) Immunoblots and quantitative analysis of PLCβ4 G), p-PLCγ1 H), p-CREB (Ser133) I), and BDNF J), n = 4. K) After knocking down PLCβ4, hippocampal neurons were treated with an mGluR1 agonist for 24 h, and the mRNA levels of BDNF-I, BDNF-IV, and BDNF-VI were assessed by qPCR, n = 3. L) The representative images of Tuj1+ hippocampal neurons (red) treated with Ro-01–6128 before the knock-down of PLCβ4 (Scale bar: 50 µm) and the quantification of average neurite length, n = 3. After transfection with 60 nM si-PLCβ4 for 24 h, mGluR1 agonist (Ro-01–6128, 10 μM) and CdCl2 (2 μM) were administered to hippocampal neurons for 24 h. M-Q) The representative immunoblots M) and quantification of PLCβ4 N), p-PLCγ1 O), p-CREB (Ser133) P), and BDNF Q), n = 3. R-S) The representative images of MAP2+ hippocampal neurons (Scale bar: 50 µm) and the quantification of average neurite length, n = 3. The hippocampal neurons were transfected with si-PLCβ4 for 24 h, followed by the treatment of TrkB inhibitor ANA-12 (10 nM) with or without CdCl2 (2 μM) for 24 h. T, W) The expression levels of PLCβ4 and p-TrKB (Tyr706) were detected by Western blotting, n = 3/4. U-V, X-Y) The representative images of MAP2+ hippocampal neurons (Scale bar: 50 µm) and the quantification of average neurite length, n = 3. Data are represented as the mean ± SEM. Statistical significance are calculated by one-way ANOVA with Tukey’s post-hoc test and Student’s t test. * P 
3). Purkinje-cell-specific MeCP2 deficiency leads to motor deficits and autistic-like behavior due to aberrations in PTP1B-TrkB-SK signaling. Cell reports, 2023 (PubMed: 38100348) [IF=7.5]
4). SIRT3 alleviates mitochondrial dysfunction induced by recurrent low glucose and improves the supportive function of astrocytes to neurons. Free Radical Biology and Medicine, 2022 (PubMed: 36306990) [IF=7.1]
5). Crosstalk between the muscular estrogen receptor α and BDNF/TrkB signaling alleviates metabolic syndrome via 7, 8-dihydroxyflavone in female mice. Molecular Metabolism, 2021 (PubMed: 33352311) [IF=7.0]

Application: WB    Species: mouse    Sample: skeletal muscle and adipose

Figure 3.| Effect of 7,8-DHF treatment on gene and protein levels of ERα and ERβ in both skeletal muscle and adipose tissues.(E)–(F) Western blotting analysis of skeletal muscle and adipose tissues isolated from mice that have been treated with 7,8-DHF for 24 weeks. Protein levels of ERα and its two phosphorylated forms p-S118 and p-Y537, the phosphorylation of TrkB and two key energy metabolism-related proteins, AKT and UCP1 were measured. Representative immunoblots and quantification are shown (n = 3 per group. *p <0.05, **p < 0.01, N.S: not significant, LFD control vs. LFD+DHF10, Student’s t test; &p < 0.05, &&p < 0.01, N.S: not significant, HFD control vs. HFD+DHF5, Student’s t test).
6). Kaempferol-3-O-sophoroside (PCS-1) contributes to modulation of depressive-like behaviour in C57BL/6J mice by activating AMPK. British journal of pharmacology, 2023 (PubMed: 37949672) [IF=6.8]
7). The role of BDNF transcription in the antidepressant-like effects of 18β-glycyrrhetinic acid in a chronic social defeat stress model. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2024 (PubMed: 38851983) [IF=6.7]
8). The role of BDNF transcription in the antidepressant-like effects of 18β-glycyrrhetinic acid in a chronic social defeat stress model. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2024 (PubMed: 38851983) [IF=6.7]
9). Ketamine attenuates kidney damage and depression-like behaviors in mice with cisplatin-induced acute kidney injury. Translational psychiatry, 2024 (PubMed: 39521765) [IF=5.8]
10). TAT-Ngn2 Enhances Cognitive Function Recovery and Regulates Caspase-Dependent and Mitochondrial Apoptotic Pathways After Experimental Stroke. Frontiers in Cellular Neuroscience, 2018 (PubMed: 30618628) [IF=5.3]
Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.